Maxim downgraded Augmedix to Hold from Buy and removed the firm’s prior $5 price target. The firm cites a more competitive market, slowing buying decisions and users switching to lower priced options following the company’s quarterly report and guidance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix Inc (AUGX) Q1 Earnings Cheat Sheet
- Augmedix to Participate in Upcoming Investor Conferences in May and June 2024
- Augmedix announces general availability of Augmedix Go
- Augmedix upgraded to Outperform from In Line at Evercore ISI
- Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care